Metrics raised 2
- India growth guidance for FY27 raised to ~12% (slightly better than earlier guidance)
- Consolidated tax rate guidance for FY27 raised to ~30-32% (from earlier lower guidance, as prior 27-28% was standalone only)
Metrics cut 2
- Ocutech FY27 target cut to ~₹400 crores sales and breakeven EBITDA (slightly off original guidance due to integration delay)
- Denosumab biosimilar US approval delayed by a few months (missed PDUFA goal date, launch pushed out)
Event Participants
Executives
3 Nitin Agrawal, Purvi Shah, Sandeep Singh
Analysts
8 Abdulkader Puranwala, Amlan Jyoti Das, Kunal Dhamesha, Kunal Randeria, Rashmmi Shetty, Saion Mukherjee, Sandeep Kumar, Tushar Manudhane
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹3,740 crores | +10.9% YoY |
| India Sales | ₹2,497 crores | +10.3% YoY; dragged by flattish trade generics, branded business grew 12% |
| International Sales | ₹1,222 crores | +16% YoY; growth led by non-US markets (Germany, Australia, Chile) |
| EBITDA Margin | 20.5% | +370 bps YoY; aided by better product mix (lower trade generics) and favorable currency |
| R&D Expenses | ~4% of revenue | Consistent with strategic focus on biosimilars pipeline |
| Profit Before Tax | ~Flattish | +1.8% YoY growth |
| Net Profit | Declined 21.7% YoY | Decline purely due to higher consolidated tax rate (~32% vs. guided); operational performance stable |
| India Growth (IQVIA) | +13.2% YoY | 100 bps outperformance vs. IPM growth of 12.2% |
| Acute Segment Growth | +12.3% YoY | 220 bps outperformance vs. IPM acute growth of 10.1% |
| Chronic Segment Growth | +17.9% YoY | 250 bps outperformance vs. IPM chronic growth of 15.4% |
| Gross Margin Guidance | 66.5-67% | Maintained for FY27; API price increases to impact subsequent quarters |
| Consolidated Tax Rate | ~32% | Higher than standalone due to no deferred tax assets on loss-making entities (US, Indegene) |
Geographic & Segment Commentary
India Business: Total India sales grew 10.3% YoY to ₹2,497 crores. Branded generics grew 12% while trade generics remained flat to mildly positive, dragging overall growth. Company outperformed IPM by 100 bps, with 220 bps outperformance in acute and 250 bps in chronic. Growth driven by price (+6%), new launches (+3%), and volume (+2%, excl. trade generics). Outperformed IPM in 7 key focus therapies: anti-infectives (1.1x), gastro (1.2x), vitamins/minerals (1.4x), pain (1.8x), antidiabetic (1.4x), respiratory (1.6x), and derma (1.6x).
US Business: US sales grew on the back of currency (rupee depreciation ~10% YoY), but constant currency growth was soft. Price erosion has nearly bottomed out (flattish), but volume growth remains elusive for recently launched products. The Daman facility received OAI status; 45% of US revenue comes from this facility, but supplies continue uninterrupted. Received 5 ANDA approvals in the quarter (1 tentative). US growth guidance maintained at mid-to-high single digits for FY27.
International (ex-US) Business: International sales grew 16% YoY to ₹1,222 crores. Non-US markets growing at strong double-digit rates, though on small bases. Germany growing 35-40%, with solid performance in Australia and Chile. Management views this growth as sustainable, but US remains dominant and will "move the needle" for the next few years.
Biosimilars (India): Launched 7 biosimilar products in India generating ~₹150 crores annualized sales. Backward integration has improved margins for these products.
Company-Specific & Strategic Commentary
US CDMO (Indegene facility): Operational since November 2025, incurred ₹60 crores quarterly OpEx. Revenue needed to break even: $25-30 million annualized run-rate. CDMO sales cycle is long and lumpy; projects are in clinical trial/development batch stage. US-FDA approval will be triggered by client filings. No capex required this year; breakeven not expected in next 12 months, targeted by FY28.
Ocutech (MedTech/Ortho Acquisition): Acquisition completed in mid-July 2026 (post-quarter); Q1 results not impacted. FY27 target: ~₹400 crores sales with breakeven EBITDA (slightly off original guidance due to integration delay). Quarterly EBITDA loss was ₹5-7 crores including diligence costs. Expect 7-8% YoY EBITDA margin improvement, reaching double-digit margins in 3-4 years.
Trade Generics Strategy: Business grew at higher single digit in Jan-Jun 2026, but Q1 FY27 was flat YoY. Management intentionally tightened credit/DSO policies and reduced inventory levels post price increases (API costs). Management comfortable with "late single digit" growth for this business given RoC dynamics; focus on execution and discipline over 1-2 years.
Daman Facility OAI: Facility received OAI status post-quarter. Comprehensive CAPA initiated; 45% of US revenue from this facility, supplies continuing without interruption. Management expects resolution in 6-12 months with no business impact this year.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| India Growth | ~12% for FY27 | Slightly better than earlier guidance, driven by branded business performance; trade generics to remain subdued |
| US Growth | Mid-to-high single digit for FY27 | Currency-supported; price erosion bottoming out; no volume growth expected; Daman OAI not expected to impact |
| Gross Margin | 66.5-67% for FY27 | Maintained; Q1 benefited from old inventory at lower API prices; API price increases to impact subsequent quarters |
| Consolidated Tax Rate | ~30-32% for FY27 | Higher than standalone (27-28%) due to no deferred tax assets on loss-making overseas entities (US, Indegene) |
| US CDMO Breakeven | FY28 (revenue $25-30M) | OPEX of ₹60 crores/quarter to continue; sales cycle lengthy; business is lumpy |
| Ocutech | ~₹400 crores sales, breakeven EBITDA in FY27 | Integration started post-July acquisition; margin improvement of 7-8% YoY; double-digit margins in 3-4 years |
| Denosumab Biosimilar (US) | Approval delayed by a few months | Missed PDUFA goal date; launch pushed out |
| Eylea (Aflibercept) Biosimilar (EU) | Launch in ~3 months | Via partner Theramex; competitive market, not expected to be significant near-term |
Risks & Constraints
| Risk | Context |
|---|---|
| Daman Facility OAI | 45% of US revenue from this facility. Supplies continuing without interruption, but OAI status could impact future ANDA approvals and potentially invite regulatory scrutiny. Management expects resolution in 6-12 months; US growth guidance maintained. |
| Trade Generics Slowdown | Segment grew flat YoY in Q1 vs. higher single digit in Jan-Jun 2026. Management tightening credit norms and reducing market inventory; competition intensifying with large players entering. Management comfortable with late single-digit growth but this drags overall India growth. |
| US CDMO Losses | Quarterly OpEx of ₹60 crores with breakeven 4-5 quarters away (FY28). Sales cycle long, projects lumpy; no revenue visibility on timing. No US-FDA approval yet; will require capex for scale-up. |
| API Price Inflation | Raw material prices increased; Q1 benefited from older inventory at lower rates. Subsequent quarters will see impact on gross margins. Guidance maintained at 66.5-67% but with caveats. |
| US Denosumab Biosimilar Delay | Missed PDUFA goal date; approval pushed by "a few months". Highly competitive market (multiple players, including in Europe). Launch ramp-up expected to be gradual, not significant near-term. |
| Currency Fluctuation | Rupee depreciation (~10% YoY) is supporting international/US revenue and margins. Any reversal would pressure reported growth and margins. |
Q&A Highlights
India Growth Dynamics
- Question: India growth at 10.3% is lower than most pharma peers; what's impacting growth and will it improve? (Saion Mukherjee, Nomura)
- Answer: Trade generics (now a significant part of domestic business) was flattish to mildly positive, dragging overall growth. Branded generics grew 12%. (Sandeep Singh)
- Follow-up on branded growth: Confirmed at 12%. (Sandeep Singh)
Cost Increases & New Business Losses
- Question: Employee cost up >16%; how much is from CDMO/MedTech and what's the EBITDA loss from these businesses? (Saion Mukherjee, Nomura)
- Answer: Three factors - annual increments, 1,200 new hires, Indegene CDMO operational since Nov 2025. US CDMO quarterly OpEx is ~₹60 crores; Ocutech had ₹5-7 crores quarterly EBITDA loss (incl. diligence costs). Ocutech to do ~₹50 crores annual sales and break even in ~12 months; US CDMO in 4-5 quarters. (Nitin Agrawal)
Biosimilar Portfolio Performance (India)
- Question: How has the 6-7 biosimilar portfolio in India performed? (Amlan Jyoti Das, J.P. Morgan)
- Answer: Seven products launched, generating ~₹150 crores annual sales. Backward integration has improved margins. (Nitin Agrawal)
Ocutech Integration & Margins
- Question: Post-July closure, how do you see Ocutech growth and margins? Does the 10% margin guidance hold? (Amlan Jyoti Das, J.P. Morgan)
- Answer: Integration delayed; FY27 target is ~₹400 crores sales with breakeven EBITDA (vs. original guidance). Expect 7-8% EBITDA margin improvement YoY; double-digit margins in 3-4 years. (Nitin Agrawal)
Daman Facility OAI - Revenue Exposure
- Question: What percentage of US revenue comes from Daman facility and are all products still supplied? (Amlan Jyoti Das, J.P. Morgan)
- Answer: Approximately 45% of US revenue. All products continue to be supplied without interruption. (Sandeep Singh)
Trade Generics - Industry vs. Company Specific
- Question: Is the trade generics slowdown industry-wide or company-specific? (Kunal Dhamesha, Macquarie)
- Answer: Combination of both - competition intensified as large players entered; internally, tightened credit/DSO norms and increased prices (API costs), leading to lower market inventory. Jan-Jun grew higher single digit, Q1 flat YoY. Recovery expected in coming quarters. (Sandeep Singh, Nitin Agrawal)
US CDMO - Scale & Timeline
- Question: What revenue is needed for US CDMO to break even, and what's the pipeline visibility? (Kunal Dhamesha, Macquarie)
- Answer: Need $25-30 million annualized revenue to break even. Not expected in next 12 months. Facility does mAbs (development to clinical trial supplies). Sales cycle is long and lumpy; patience required. Not US-FDA approved yet - will be triggered by client filings. Capex needed eventually, but not this year. (Sandeep Singh)
Trade Generics Growth Ambition
- Question: What timeline for trade generics to bounce back to at least branded growth levels? (Abdulkader Puranwala, ICICI Securities)
- Answer: Matching branded growth is "very hard." Personally comfortable with late single-digit growth; need execution and discipline in the business for next 1-2 years. RoC is good, no capex requirement. (Sandeep Singh)
CEO Search Update
- Question: Any update on hiring a CEO? (Abdulkader Puranwala, ICICI Securities)
- Answer: Still looking; critical hire, can't hurry. Hopefully by next quarterly call, the person will be present. (Sandeep Singh)
Consolidated Tax Rate Guidance
- Question: Is the 27-28% tax rate guidance still valid? (Abdulkader Puranwala, ICICI Securities)
- Answer: That was for standalone. Consolidated will be ~30-32% because loss-making entities (US CDMO, Indegene) don't have deferred tax assets created. (Nitin Agrawal)
India Business - Price/Volume Split & Semaglutide Impact
- Question: What was the price-volume-new launch split for India (excl. trade generics)? How much benefit from Semaglutide patent expiry? (Tushar Manudhane, Motilal Oswal)
- Answer: Price growth ~6%, new launches ~3%, volume ~2%. Semaglutide benefit is very small right now, but Alkem is among top 3 in generics. IPM growth sustainability driven by chronic segment (Semaglutide patent expiry). (Nitin Agrawal, Sandeep Singh)
US Business - Constant Currency Softness
- Question: US looks soft in constant currency; what's the full-year outlook considering Daman OAI? (Rashmmi Shetty, Dolat Capital)
- Answer: Daman OAI is a concern but won't impact business this year - supplies continuing, and resolution expected in 6-12 months. Price erosion nearly flattish/bottomed out. No volume growth; growth will be currency-driven. FY27 US guidance: mid-to-high single digit. (Sandeep Singh)
Non-US International Sustainability
- Question: Is the double-digit international growth (ex-US) sustainable? (Amlan Jyoti Das, J.P. Morgan)
- Answer: Quite sustainable. Germany growing 35-40%, Australia and Chile doing well. But on small base; US will still "move the needle" for next few years. (Sandeep Singh)
Gross Margin Improvement Drivers
- Question: Why did gross margins improve and what's the outlook? (Amlan Jyoti Das, J.P. Morgan)
- Answer: Better mix (lower trade generics, better branded performance), currency tailwinds (US, Australia). Maintain guidance of 66.5-67% - API price increases will impact subsequent quarters when new inventory is consumed. (Nitin Agrawal)
Key Takeaway
Alkem Laboratories delivered a mixed Q1 FY27: revenue grew 11% YoY to ₹3,740 crores with India at 10.3% (branded 12%, trade generics flat) and international up 16%, while EBITDA margin expanded 370 bps to 20.5%. Net profit declined 21.7% solely due to a higher consolidated tax rate (32%) from loss-making overseas entities. India outperformed IPM by 100 bps with strong showings in chronic (+17.9%) and acute (+12.3%). Strategically, the company is investing in new growth engines - US CDMO (₹60 crores quarterly OpEx) and MedTech/Ocutech (₹400 crores FY27 sales target) - while advancing a 7-product India biosimilar portfolio (~₹150 crores annual sales). Key watch items include the Daman facility OAI (45% of US revenue), API price inflation impacting gross margins in coming quarters, and delayed Denosumab approval in the US. Management maintained India growth guidance of ~12% and US mid-to-high single digit for FY27, with CDMO breakeven targeted for FY28.